NOXOPHARM-LIMITED
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda® ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease. Based on initial positive results, Noxopharm has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
The relevance of blocking TBK1 is seen as important in two respects: (i) ability to block a dysfunctional immune response to RNA viruses such as coronavirus and influenza virus; (ii) potential to avoid the adverse immune-suppressing effects of standard anti-inflammatory drugs such as prednisone and dexamethasone in potentially slowing viral clearance and increasing the risk of secondary infections.
“The NOXCOVID Phase I clinical trial is highly encouraging for Veyonda in this role as a high proportion of the patients were experiencing elevated inflammation,” said Noxopharm CEO and Managing Director Graham Kelly . “In this trial, no major safety issues were identified and 37 of 38 patients hospitalized with moderate respiratory disease recovered.”
“Based on what is known today, Veyonda’s properties give it the potential to address a gap in our armory of COVID-19 therapeutics,” said Marcel Nold , M.D., professor of pediatric immunology at Monash University and the Hudson Institute and pediatrician at Monash Children’s Hospital. “Patients can self-administer, allowing its use in their own home. Its mechanism of action may enable treatment of moderately ill COVID-19 patients and, importantly, it could also be effective against many other viruses. In Veyonda, Noxopharm has an exciting opportunity at hand.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAMPHENOM Europe Expands All-Star Speaker Lineup27.10.2025 14:30:00 CET | Press release
Newly Confirmed Speakers to Deliver What HR Leaders Need: AI Strategy, Proven Solutions and Bold Talent Thinking Phenom, an applied AI company that helps organisations hire faster, develop better and retain longer, announced a second wave of confirmed speakers joining its inaugural IAMPHENOM Europe conference — the only applied AI event for human resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027606156/en/ Phenom announced a second wave of confirmed speakers joining its inaugural IAMPHENOM Europe conference — the only applied AI event for human resources. Featuring visionary keynotes, customer-led breakout sessions, live demonstrations of use-case specific AI agents, and networking opportunities across HR and IT, the in-person event will take place 6 November in Munich. Session topics will include how to: assess AI and automation maturity levels; deploy 25+ AI agents; uphold compliance while navigating European
Klarna Launches Memberships: Premium Perks Without Expensive Credit27.10.2025 14:00:00 CET | Press release
Klarna’s new Premium and Max memberships pack cashback, travel perks, and top subscriptions into one plan, delivering 10x the value with no spending targets. Klarna, the global digital bank and payments provider, today unveiled its new global membership program, introducing Premium and Max. The program delivers premium benefits like cashback, travel perks, and lifestyle rewards in a transparent, monthly plan, without the need to take on expensive credit. The launch marks a major step in Klarna’s evolution into a full-scale digital bank helping consumers manage their money with greater value and control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027643962/en/ “We believe consumers shouldn’t have to take on expensive credit to access premium benefits,” said David Sandström, Chief Marketing Officer at Klarna. “For decades, exclusive perks such as airport lounge access, concierge-style subscriptions, and premium travel i
ThetaRay and Kaufman Rossin Announce AI AML Model Validation at Money20/20 USA27.10.2025 14:00:00 CET | Press release
Independent review affirms ThetaRay’s transaction monitoring and sanctions screening modules meet rising U.S. and EU regulatory expectations. ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced that Kaufman Rossinhas completed an independent validation of its AML Transaction Monitoring and OFAC Screening Modules. Finalized in August 2025, the review confirms that ThetaRay’s AI models demonstrate the governance, transparency, and robustness regulators increasingly expect from AI-driven compliance systems. The announcement will be featured at Money20/20 USA, where the future of finance and compliance technology takes center stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027724792/en/ A timely milestone in a shifting regulatory landscape In the United States, regulators are sharpening their focus on model risk management. FinCEN’s proposed modernization of the Bank Secrecy Act emphasi
SLB and Ormat Partner to Accelerate Integrated Geothermal Asset Development and Enhanced Geothermal Systems27.10.2025 14:00:00 CET | Press release
New geothermal agreement aims to advance hydrothermal projects; develop and deploy EGS at scale Global energy technology company SLB (NYSE: SLB) and leading geothermal and renewable energy company Ormat Technologies (NYSE: ORA) today announced an agreement to fast-track the development and commercialization of integrated geothermal assets, including enhanced geothermal systems (EGS). EGS is the next generation of geothermal technology, meant to unlock geothermal energy in regions beyond where conventional geothermal resources exist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251025805256/en/ The Ormat geothermal facility Casa Diablo IV, California Together, SLB and Ormat intend to streamline project deployment, from concept to power generation. As part of this effort, they will develop, pilot and scale EGS solutions to enable wide-scale EGS adoption. This collaboration will include the design and construction of an EGS p
inDrive Calls for Justice in Tech Leadership; Launches Global Campaign to Recruit Directors for Child Protection, Education, and Good Governance27.10.2025 14:00:00 CET | Press release
Ride-sharing platform extends mission-driven approach from business model to hiring practices, seeking leaders who view social justice as core business strategy inDrive, the world’s second most downloaded ride-hailing app, has set a bold goal: to positively impact 1 billion people by 2030. To achieve it, the company is strengthening its impact arm and launching “Positions of Purpose,” a global campaign to recruit senior leaders in child protection, education, and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027308855/en/ inDrive, a global mobility and urban services platform, extends mission-driven approach from business model to hiring practices. inDrive first challenged the ride-hailing model by allowing riders and drivers to negotiate fares directly, building a business on fairness instead of opaque pricing. Now, the company is challenging what impact hiring should look like — putting social justice roles
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom